EC Neurology

Parkinson's disease (PD) is an insidious, slowly progressing neurodegenerative disease affecting the nigrostriatal pathway in the brain. Levodopa-carbidopa intestinal gel (LCIG) is one of the best device-assisted therapies used in advanced-stage Parkinson's disease. The crucial complications of this treatment are rare and mostly due to percutaneous gastrostomy. This manuscript presents two rare catheter complications of percutaneous gastrostomy with levodopa-carbidopa intestinal gel therapy.

Keywords: Advanced Stage Parkinson's Disease; LCIG; Device-Assisted Therapy

1. Mhyre TR., et al. “Parkinson’s disease”. Subcellular Biochemistry 65 (2013): 389-455.
2. Hayes MT. “Parkinson’s Disease and Parkinsonism”. American Journal of Medicine 132 (2019): 802-807.
3. Esmail S. “The Diagnosis and Management of Parkinson’s Disease Article Information”. Scholar Journal of Applied Sciences and Research 1 (2018).
4. Luquin M-R., et al. “Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study)”. Teive H, editor. Park District (2017): 4047392.
5. Timpka J., et al. “Device-Aided Treatment Strategies in Advanced Parkinson’s Disease”. International Review of Neurobiology 132 (2017): 453-474.
6. Cerrone P., et al. “Phytobezoar and duodenal ulcer as complication of Duodopa therapy in a patient affected by Parkinson’s disease”. BMJ Case Reports (2018): bcr-2017-223884.
7. Aradi SD and Hauser RA. “Medical Management and Prevention of Motor Complications in Parkinson’s Disease”. Neurotherapeutics4 (2020): 1339-1365.
8. Skodda S. “Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson and #39;s disease”. Restless Legs Syndrome and Parkinson Disease (2014).
9. Sücüllü Karadağ Y., et al. “Comprehensive assessment of levodopa-carbidopa intestinal gel for turkish advanced parkinson’s disease patients”. Turkish Journal of Medical Sciences 1 (2021): 84-89.
10. Paschos KA and Chatzigeorgiadis A. “Pathophysiological and clinical aspects of the diagnosis and treatment of bezoars”. Annals of Gastroenterology 3 (2019): 224-232.
11. Poirier A-A., et al. “Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments. Wu S-L, editor”. Park District (2016): 6762528.
12. Abu-Heija AA., et al. “Delayed Diagnosis of Buried Bumper Syndrome When Only the Jejunostomy Extension is Used in a Percutaneous Endoscopic Gastrostomy-jejunostomy Levodopa-carbidopa Intestinal Gel Delivery System”. Cureus 4 (2019): e4568-e4568.
13. Stathis P., et al. “Gastric bezoar complication of Duodopa® therapy in Parkinson’s disease, treated with Coca-Cola®”. Movement Disorders 8 (2014): 1087-1088.
14. Taki S., et al. “Migration of a percutaneous endoscopic gastrojejunostomy tube into the colon with small intestinal telescoping”. Clinical Endoscopy 6 (2019): 616-619.
15. Krones E., et al. “Knotting of percutaneous endoscopic jejunostomy feeding tubes in two patients with Parkinsons disease and continuous Duodopa ® treatment”. Zeitschrift für Gastroenterologie 2 (2012): 213-216.
16. Udd M., et al. “Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease”. Brain and Behavior 7 (2017): 1-7.
17. Nyholm D and Lennernäs H. “Irregular gastrointestinal drug absorption in Parkinson's disease”. Expert Opinion on Drug Metabolism and Toxicology 2 (2008): 193-203.
18. Del-Hoyo-Francisco J., et al. “Knotting of Duodopa® duodenal infusion system”. Revista Espanola de Enfermedades Digestivas5 (2015): 323-324.